Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ALDR is in the long-term down -72% below S&P in 7 years.
Description: Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-4.47||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-3.91|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-0.14%||ROE||-0.15%||ROI|
|Current Ratio||36.49||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.03|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||190.83 M||Cash From Investing Activities||-11.65 M||Cash From Operating Activities||-16.05 M||Gross Profit|
|Net Profit||-14.65 M||Operating Profit||-14.71 M||Total Assets||242.94 M||Total Current Assets||241.6 M|
|Total Current Liabilities||6.62 M||Total Debt||Total Liabilities||6.78 M||Total Revenue|
|High 52 week||18.6||Low 52 week||8.87||Last close||9.38||Last change||-6.11%|
|RSI||38.94||Average true range||0.47||Beta||1.71||Volume||534.94 K|
|Simple moving average 20 days||-6.72%||Simple moving average 50 days||-14.14%||Simple moving average 200 days||-23.17%|
|Performance Week||0.86%||Performance Month||-18.58%||Performance Quart||-17.36%||Performance Half||-32.18%|
|Performance Year||-31.78%||Performance Year-to-date||-8.49%||Volatility daily||3.6%||Volatility weekly||8.05%|
|Volatility monthly||16.51%||Volatility yearly||57.18%||Relative Volume||264.97%||Average Volume||868.2 K|
|New High||New Low|
2019-12-05 20:15:22 | Azelby out as CEO of Alder BioPharmaceuticals following close of $2B acquisition
2019-11-22 03:01:00 | Seattle has potential as a biotech hub, but more companies must stay here and grow
2019-10-28 19:56:55 | Did Hedge Funds Drop The Ball On On Alder Biopharmaceuticals Inc ALDR ?
2019-10-15 09:00:01 | All You Need to Know About Alder BioPharmaceuticals ALDR Rating Upgrade to Strong Buy
2019-10-09 18:18:23 | This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks
2019-10-01 19:17:00 | INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alder BioPharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-09-26 05:42:09 | Use Rising P/E Strategy to Grab 5 Winning Stocks
2019-09-18 10:33:02 | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
2019-09-17 18:14:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.
2019-09-17 12:29:15 | A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019
2019-09-17 10:29:02 | Company News For Sep 17, 2019
2019-09-17 09:26:01 | Alder ALDR Stock Up on Acquisition Agreement With Lundbeck
2019-09-16 16:17:38 | This Biotech Stock Just Rocketed 84% On A $2 Billion Takeover Deal
2019-09-16 13:22:00 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Alder BioPharmaceuticals, Inc. NASDAQ: ALDR on Behalf of Alder Shareholders and Encourages Alder Investors to Contact the Firm
2019-09-16 13:15:42 | A Look At Benzinga Pro's Most-Searched Tickers For September 16, 2019
2019-09-16 12:22:16 | Alder Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Alder Biopharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact The Firm – ALDR
2019-09-16 10:19:31 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Alder BioPharmaceuticals, Inc. to H. Lundbeck A/S is Fair to Shareholders
2019-09-16 09:19:43 | Danish Company To Buy Migraine Drug Developer Alder Biopharma In Deal Worth Up To $1.95B
2019-09-16 08:29:00 | Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal
2019-09-16 05:31:00 | [video]Alder Biopharmaceuticals Surges on Lundbeck Offer
2019-09-16 02:10:06 | Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals
2019-09-16 01:55:52 | Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash
2019-09-10 10:29:02 | Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
2019-08-30 16:01:00 | Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635c4
2019-08-28 16:01:00 | Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences
2019-08-22 12:01:04 | MyoKardia Begins Dosing in Phase I Study on Heart Candidate
2019-08-21 11:08:03 | NuCana Stops Patient Enrollment in Pancreatic Cancer Study
2019-08-16 11:23:03 | What's in Store for Aytu BioScience's AYTU Q4 Earnings?
2019-08-15 20:12:51 | Alder BioPharmaceuticals approaches rare status for a Seattle biotech
2019-08-15 20:12:51 | Alder on hiring binge ahead of FDA ruling
2019-08-07 19:48:17 | Alder BioPharmaceuticals, Inc. ALDR Q2 2019 Earnings Call Transcript
2019-08-07 03:34:09 | Edited Transcript of ALDR earnings conference call or presentation 6-Aug-19 9:00pm GMT
2019-08-06 16:07:00 | Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
2019-08-02 16:01:00 | Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635c4